Tenax Therapeutics, Inc. (TENX) – What Are Analysts Thinking About This Stock?

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) have been given an average rating of “Hold” by the ten brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $14.00.

A number of research firms have weighed in on TENX. Canaccord Genuity Group set a $4.00 target price on shares of Tenax Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Roth Capital set a $5.00 price target on Tenax Therapeutics in a research report on Monday, August 10th. Guggenheim cut Tenax Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 31st. Evercore downgraded Tenax Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective on the stock. in a research report on Tuesday, August 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Tenax Therapeutics in a report on Thursday, September 10th.

Key Tenax Therapeutics News

Here are the key news stories impacting Tenax Therapeutics this week:

• Neutral Sentiment: Investors who purchased Tenax securities between November 13, 2023, and August 7, 2026, may seek appointment as lead plaintiff. The stated deadline is December 28, 2026. Several firms, including Rosen Law Firm, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, and Portnoy Law, issued investor notices. Rosen Law Firm securities fraud lawsuit notice
• Negative Sentiment: The lawsuit, filed in federal court against Tenax and certain officers, seeks damages under federal securities laws. Repeated announcements from multiple law firms increase the visibility of the litigation and add legal, financial, and reputational risk for shareholders. Pomerantz class-action filing
• Negative Sentiment: Shareholder allegations include claims that Tenax overstated the effectiveness of its lead candidate TNX-103, as well as its clinical, regulatory, and commercial prospects. Other complaints allege investors were misled about the viability of the company’s levosimendan program. These are allegations, not proven findings, but they directly challenge the company’s core investment thesis. Holzer and Holzer investor alert

Tenax Therapeutics Price Performance

Shares of Tenax Therapeutics stock opened at $1.88 on Friday. The business has a 50 day simple moving average of $1.84 and a two-hundred day simple moving average of $10.23. Tenax Therapeutics has a 12 month low of $1.31 and a 12 month high of $19.40. The stock has a market capitalization of $70.36 million, a P/E ratio of -1.27 and a beta of 0.92.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. As a group, research analysts anticipate that Tenax Therapeutics will post -1.38 EPS for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Adar1 Capital Management, Llc bought 900,000 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were bought at an average cost of $1.78 per share, for a total transaction of $1,602,000.00. Following the acquisition, the insider directly owned 6,524,151 shares of the company’s stock, valued at $11,612,988.78. This trade represents a 16.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have bought 3,682,899 shares of company stock worth $6,388,279 over the last quarter. 10.81% of the stock is owned by insiders.

Institutional Trading of Tenax Therapeutics

Several hedge funds have recently made changes to their positions in TENX. State of Alaska Department of Revenue acquired a new position in shares of Tenax Therapeutics in the 3rd quarter worth approximately $94,000. Bank of America Corp DE boosted its position in shares of Tenax Therapeutics by 391.2% during the 1st quarter. Bank of America Corp DE now owns 18,569 shares of the specialty pharmaceutical company’s stock worth $297,000 after purchasing an additional 14,789 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Tenax Therapeutics during the 2nd quarter worth approximately $485,000. The Manufacturers Life Insurance Company acquired a new stake in Tenax Therapeutics in the 1st quarter valued at approximately $501,000. Finally, Dimensional Fund Advisors LP acquired a new stake in Tenax Therapeutics in the 1st quarter valued at approximately $1,001,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.